Literature DB >> 24226422

CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens.

Junpei Furuta1, Takashi Inozume2, Kazutoshi Harada1, Shinji Shimada1.   

Abstract

IFN-γ released from cytotoxic T lymphocytes (CTLs) during the effector phase is essential for rejecting bulky melanoma tumors. In contrast, IFN-γ is known to induce certain immunosuppressive factors in tumor cells such as programmed cell death 1 ligand 1 (PD-L1). In this study, we have identified candidates for IFN-γ-inducible CTL-suppressive factors in melanoma cells using complementary DNA microarray analysis, and CD271/p75/neurotrophin receptor (NTR) was one of the candidate genes. Recently, CD271 was identified as a marker of the cancer stem cell-like population in human melanoma tissues. In this study, we showed that overexpression of CD271 on melanoma cells suppressed the in vitro activation of melanoma-specific CTLs. This suppression was mediated by CD271 ligation with activated CTL-derived nerve growth factor and the subsequent downregulation of melanoma antigens. Moreover, we found that the expression levels of PD-L1 on melanoma cells correlated with those of CD271, and they additively suppressed the activation of melanoma-specific CTLs. To the best of our knowledge, the role of overexpression of CD271 in an anti-melanoma T-cell response has been unreported.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24226422     DOI: 10.1038/jid.2013.490

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  17 in total

Review 1.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

2.  Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.

Authors:  Ryosuke Hino; Kenji Kabashima; Yu Kato; Hiroaki Yagi; Motonobu Nakamura; Tasuku Honjo; Taku Okazaki; Yoshiki Tokura
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

3.  Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity.

Authors:  Naotaka Shibagaki; Mark C Udey
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.

Authors:  Takashi Inozume; Ken-Ichi Hanada; Qiong J Wang; Mojgan Ahmadzadeh; John R Wunderlich; Steven A Rosenberg; James C Yang
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

6.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

7.  Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.

Authors:  Alexander D Boiko; Olga V Razorenova; Matt van de Rijn; Susan M Swetter; Denise L Johnson; Daphne P Ly; Paris D Butler; George P Yang; Benzion Joshua; Michael J Kaplan; Michael T Longaker; Irving L Weissman
Journal:  Nature       Date:  2010-07-01       Impact factor: 49.962

8.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

9.  Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.

Authors:  Douglas C Palmer; Chi-Chao Chan; Luca Gattinoni; Claudia Wrzesinski; Chrystal M Paulos; Christian S Hinrichs; Daniel J Powell; Christopher A Klebanoff; Steven E Finkelstein; Robert N Fariss; Zhiya Yu; Robert B Nussenblatt; Steven A Rosenberg; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-03       Impact factor: 11.205

Review 10.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

View more
  22 in total

1.  A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies.

Authors:  Alexander K Tsai; Asra Y Khan; Christina E Worgo; Lucy L Wang; Yuanyuan Liang; Eduardo Davila
Journal:  Cancer Immunol Res       Date:  2017-08-03       Impact factor: 11.151

2.  A stress-induced early innate response causes multidrug tolerance in melanoma.

Authors:  D Ravindran Menon; S Das; C Krepler; A Vultur; B Rinner; S Schauer; K Kashofer; K Wagner; G Zhang; E Bonyadi Rad; N K Haass; H P Soyer; B Gabrielli; R Somasundaram; G Hoefler; M Herlyn; H Schaider
Journal:  Oncogene       Date:  2014-11-24       Impact factor: 9.867

3.  NFATc2 is an intrinsic regulator of melanoma dedifferentiation.

Authors:  V Perotti; P Baldassari; A Molla; C Vegetti; I Bersani; A Maurichi; M Santinami; A Anichini; R Mortarini
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

4.  Understanding melanoma stem cells.

Authors:  Nicholas Nguyen; Kasey L Couts; Yuchun Luo; Mayumi Fujita
Journal:  Melanoma Manag       Date:  2015

5.  Therapeutic implications of melanoma heterogeneity.

Authors:  Stephanie J Hachey; Alexander D Boiko
Journal:  Exp Dermatol       Date:  2016-05-19       Impact factor: 3.960

6.  Durable antitumor responses to CD47 blockade require adaptive immune stimulation.

Authors:  Jonathan T Sockolosky; Michael Dougan; Jessica R Ingram; Chia Chi M Ho; Monique J Kauke; Steven C Almo; Hidde L Ploegh; K Christopher Garcia
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

Review 7.  Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.

Authors:  Zhong-Yi Dong; Si-Pei Wu; Ri-Qiang Liao; Shu-Mei Huang; Yi-Long Wu
Journal:  Tumour Biol       Date:  2016-01-16

Review 8.  Interplay between inflammatory tumor microenvironment and cancer stem cells.

Authors:  Shijian Zhang; Xi Yang; Lei Wang; Chenping Zhang
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

9.  Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer.

Authors:  Anders Josefsson; Jessie R Nedrow; Sunju Park; Sangeeta Ray Banerjee; Andrew Rittenbach; Fabien Jammes; Benjamin Tsui; George Sgouros
Journal:  Cancer Res       Date:  2015-11-10       Impact factor: 12.701

10.  Melanoma Cell State-Specific Responses to TNFα.

Authors:  Su Yin Lim; Sara Alavi; Zizhen Ming; Elena Shklovskaya; Carina Fung; Ashleigh Stewart; Helen Rizos
Journal:  Biomedicines       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.